CRISPR pays to partner with ViaCyte on an off-the-shelf gene-editing approach to curing diabetes
ViaCyte has been developing a line of pancreatic cells out of stem cells, looking for a regenerative medicine approach to treating Type 1 diabetes.
But there’s a big drawback. These cells are seen by the immune system as foreign, so in order for it to work, diabetics’ immune system has to be suppressed — with obvious potential for harm.
Now, CRISPR Therapeutics $CRSP, one of the leaders in CRISPR/Cas9 gene editing with a big interest in regenerative medicine, is stepping in to use their immune-evasive tech to create a new line of cells that can do the job without kicking in the rejection response.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.